1.35
+0.1(+8.00%)
Currency In USD
| Previous Close | 1.25 |
| Open | 1.33 |
| Day High | 1.39 |
| Day Low | 1.25 |
| 52-Week High | 3.83 |
| 52-Week Low | 0.25 |
| Volume | 2.89M |
| Average Volume | 1.18M |
| Market Cap | 99.34M |
| PE | -5.87 |
| EPS | -0.23 |
| Moving Average 50 Days | 1.11 |
| Moving Average 200 Days | 1.44 |
| Change | 0.1 |
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis
GlobeNewswire Inc.
Mar 02, 2026 12:30 PM GMT
We believe regulatory strategy expedites development of potential first treatment to address DLB psychosisPURCHASE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage c
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
GlobeNewswire Inc.
Feb 05, 2026 12:30 PM GMT
PURCHASE, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, has extended the duration of the expand
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
GlobeNewswire Inc.
Jan 27, 2026 12:30 PM GMT
PURCHASE, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted a Type C meeting with the U.S. Fo